Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03062358 |
|
Recruitment Status :
Active, not recruiting
First Posted : February 23, 2017
Last Update Posted : March 4, 2022
|
Sponsor:
Merck Sharp & Dohme LLC
Information provided by (Responsible Party):
Merck Sharp & Dohme LLC
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Active, not recruiting |
|---|---|
| Actual Primary Completion Date : | June 30, 2021 |
| Estimated Study Completion Date : | June 30, 2023 |
| Submission Cycle | Results Submitted to ClinicalTrials.gov | Results Returned after Quality Control Review |
|---|---|---|
| 1 |
June 7, 2022 |